Treatment of early arthritis using arthrofoon (ultra-low doses of antibodies to tumor necrosis factor-)

Indian Journal of Pharmacology

Volumn 43, Issue 6, 2011, Pages 724-725

  Sizova, Lyudmila V ^a  

^a ORENBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arthrofoon; early arthritis; undifferentiated arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; ARTHROFOON; C REACTIVE PROTEIN; NIMESULIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; PERIARTHRITIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SYNOVITIS; TENOSYNOVITIS;

EID: 81855228741     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.89836     Document Type: Conference Paper

References (3)

1. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review. Arthritis Res Ther 2009;11 (Suppl 1):S1.
2. Yamaguchi Y, Yamamoto K. New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction. Clin Calcium 2007;117:463-73.
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3 rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.